Search
Hydroxocobalamin
go.drugbank.com/drugs/DB00200ApprovedInvestigationalIt is also used in cyanide poisoning, Leber's optic atrophy, and toxic amblyopia. … Hydroxocobalamin, also known as vitamin B12a and hydroxycobalamin, is an injectable form of vitamin B 12 that has been used therapeutically to treat vitamin B 12 deficiency.
Voxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalwith an HCV regimen containing sofosbuvir without an NS5A inhibitor [L935]. … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigational[L43882] On November 3rd 2022, Health Canada also approved the Moderna Bivalent Vaccine as a booster shot in individuals 18 years of age or older.[L43862] … [L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt
Hexafluronium
go.drugbank.com/drugs/DB00941ApprovedHexafluronium bromide is a neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of suxamethonium during surgery.
Oxamniquine
go.drugbank.com/drugs/DB01096Approved(From Martidale, The Extra Pharmacopoeia, 31st ed, p121) … An anthelmintic with schistosomicidal activity against Schistosoma mansoni, but not against other Schistosoma spp.
Pinacidil
go.drugbank.com/drugs/DB06762ApprovedThe above processes result in reduced blood pressure. This drug has been discontinued by the FDA.
Categories: Arteriolar Smooth Muscle, Agents Acting OnBenzethonium
go.drugbank.com/drugs/DB11125ApprovedIt is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments. … It is shown to be effective in mediating its antimicrobial action against bacteria, fungi, mold and viruses.
Products: Ben E. Keith Foam Sanitizer, Hand-E-foamAtracurium besylate
go.drugbank.com/drugs/DB00732ApprovedIts lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents
Atezolizumab
go.drugbank.com/drugs/DB11595ApprovedInvestigational[L7489] Atezolizumab was granted FDA approval on 18 October 2016. … Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigational[L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.